Oligoastrocytoma causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Common causes of oligoastrocytoma include genetic mutations. Common genetic mutations involved in the development of oligoastrocytoma can be found here.

Causes

Common causes of oligoastrocytoma include genetic mutations. The genes associated with the etiology of oligoastrocytoma include:^[1]^[2]^[3]^[4]^[5]^[6]

IDH1
t(1;19)(q10;p10)
p53
ATRX
EGFR
PTEN
MGMT
CIC
FUBP1

References

↑ Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). “Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets”. Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.
↑ Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S; et al. (2014). “Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma”. Acta Neuropathol. 128 (4): 551–9. doi:10.1007/s00401-014-1326-7. PMID 25143301.
↑ Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F; et al. (2008). “Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas”. Anticancer Res. 28 (2A): 913–20. PMID 18507036.
↑ Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR; et al. (2002). “Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival”. Clin Cancer Res. 8 (5): 1100–6. PMID 12006525.
↑ van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG; et al. (2013). “MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951”. Clin Cancer Res. 19 (19): 5513–22. doi:10.1158/1078-0432.CCR-13-1157. PMID 23948976.
↑ Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF; et al. (2012). “Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas”. Oncotarget. 3 (7): 709–22. PMC 3443254. PMID 22869205.

Template:WikiDoc Sources

[pmid12107116-1] Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). “Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets”. Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.

[pmid25143301-2] Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S; et al. (2014). “Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma”. Acta Neuropathol. 128 (4): 551–9. doi:10.1007/s00401-014-1326-7. PMID 25143301.

[pmid18507036-3] Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F; et al. (2008). “Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas”. Anticancer Res. 28 (2A): 913–20. PMID 18507036.

[pmid12006525-4] Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR; et al. (2002). “Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival”. Clin Cancer Res. 8 (5): 1100–6. PMID 12006525.

[pmid23948976-5] van den Bent MJ, Erdem-Eraslan L, Idbaih A, de Rooi J, Eilers PH, Spliet WG; et al. (2013). “MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951”. Clin Cancer Res. 19 (19): 5513–22. doi:10.1158/1078-0432.CCR-13-1157. PMID 23948976.

[pmid22869205-6] Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF; et al. (2012). “Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas”. Oncotarget. 3 (7): 709–22. PMC 3443254. PMID 22869205.

[1]

[2]

[3]

[4]

[5]

[6]